Structure-activity relationship study of human liver microsomes-catalyzed hydrolysis rate of ester prodrugs of MENT by comparative molecular field analysis (CoMFA)

Steroids

Volumn 68, Issue 3, 2003, Pages 213-220

  Bursi, Roberta ^a   Grootenhuis, Arijan ^a   Van Der Louw, Jaap ^a   Verhagen, Jos ^a   De Gooyer, Marcel ^a   Jacobs, Peter ^a   Leysen, Dirk ^a  

^a NV ORGANON   (Netherlands)

Author keywords

3D QSAR; CoMFA; Ester hydrolysis; MENT; Steroid

Indexed keywords

ANDROGEN; ESTER; PRODRUG;

ARTICLE; CATALYST; CONTRACEPTION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE; DRUG HYDROLYSIS; DRUG SCREENING; ELECTRICITY; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HYDROGEN BOND; LIVER MICROSOME; METABOLISM; PROSTATE; STRUCTURE ACTIVITY RELATION;

EID: 0037334251     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(02)00186-1     Document Type: Article

References (24)

1. Vermeulen A. Andropauze. Maturitas. 34:2000;5-15.
2. Tenover J.L. Testosterone replacement therapy in older adult men. Int. J. Androl. 22:1999;300-306.
3. Anonymous. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet 1990;336:955-9.
4. Anonymous. Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. World Health Organization Task Force on methods for the regulation of male fertility. Fertil Steril 1993;60:1062-8.
5. Handelsman D.J., Farley T.M., Peregoudov A., Waites G.G.G.M. Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Fertil. Steril. 63:1995;125-133.
6. Wu F.C.W., Balasubramanian R., Mulders T.M.T., Coelingh-Bennink H.J.T. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J. Clin. Endocrin. Metab. 84:1999;112-122.
7. Martin C.W., Riley S.C., Everington D., Groome N.P., Riemersma R.A., Baird D.T., Anderson R.A. Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men. Hum. Reprod. 15:2000;1515-1524.
8. Gambineri A., Pasqualini R. Testosterone therapy in men: clinical and pharmacological perspectives. J. Endocrinol. Invest. 23:2000;196-214.
9. Davis S. Androgen replacement in women: a commentary. J. Clin. Endocrin. Metab. 84:1999;1886-1891.
10. Kumar N., Didolkar A.K., Monder C., Bardin C.W., Sundaram K. The biological activity of 7α-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology. 130:1992;3677-3683.
11. Babcock JC, Campbell JA, inventors; Upjohn Co., US, assignee. 7-Methyltestosterones. US 334155; September 12, 1967.
12. Leysen D, Van der Voort HAA, inventors; Akzo Nobel N.V., The Netherlands, assignee. Preparation of (7α,17β)-7-methyl-17-[(1-oxoundecyl)oxy]estr-4-en-3-one. EP 1998-202052; June 19, 1998.
13. Leysen D, Van der Voort HAA, Van der Louw J, inventors; Akzo Nobel N.V., The Netherlands, assignee. Preparation of cycloalkyl-carboxylic acid esters of 7α-methylestr-4-en-3-one 17β-ol (19-nor-7α-methyltestosterone). EP 1998-202051; June 19, 1998.
14. Bolt C.C., De Jongh H.P., Siegmann C.M., Van Vliet N.P., Zeelen F.J. C17-Substituted 5- and 5(10)-estrenes and their 7α-methyl homologs. Recl. Trav. Chim. Pays-Bas. 88:1969;1061-1069.
15. Cramer R.D., Patterson D.E., Bunce J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110:1988;5959-5967.
16. SYBYL 6.7; Tripos Assoc, 1699 S. Hanley Rd, St. Louis, MO 63144.
17. Stewart JJP. MOPAC 6.0. Quantum Chemical Program Exchange 455; 1990.
18. Kubinyi H. 3D QSAR in drug design: theory, methods and applications. ESCOM: Leiden; 1993.
19. Kubinyi H, Folkers G, Martin YC. 3D QSAR in drug design: recent advances. ESCOM (Kluwer): Leiden; 1997.
20. Bursi R., Grootenhuis P.D.J. Comparative molecular field analysis and energy interaction studies of thrombin-inhibitor complexes. J. Comput.-Aided Mol. Des. 13:1999;221-232.
21. Bohacek R.S., McMartin C. Definition and display of steric, hydrophobic, and hydrogen-bonding properties of ligand binding sites in proteins using Lee and Richards accessible surface: validation of a high-resolution graphical tool for drug design. J. Med. Chem. 35:1992;1671-1684.
22. Aldridge W.N. The esterases: perspectives and problems. Chem.-Biol. Interact. 87:1993;5-13.
23. Satoh T., Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu. Rev. Pharmacol. Toxicol. 38:1998;257-288.
24. Buchwald P. Structure-metabolism relationships: steric effects and the enzymatic hydrolysis of carboxylic esters. Mini Rev. Med. Chem. 1:2001;101-111.